C12Y 301/06004
N-acetylgalactosamine-6-sulfatase
Official title: N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
C12Y301/06004 (N-acetylgalactosamine-6-sulfatase) appears on 15 US grants and 21 published applications in this corpus.
Search patents in C12Y- Granted patents
- 15
- Published applications
- 21
- Assignees
- 20
- Inventors
- 50
- Latest grant
- 11 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 4 |
| 2020 | 2 | 1 |
| 2021 | 1 | 4 |
| 2022 | 1 | 2 |
| 2023 | 2 | 2 |
| 2024 | 1 | 0 |
| 2025 | 2 | 1 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of mucopolysaccharidosis IVA11 Mar 2025US 12,247,213 B2REGENXBIO Inc.
- Animal model of mucopolysaccharidoses type IVA21 Jan 2025US 12,201,095 B2Esteve Pharmaceuticals, S.A.
- Adenoassociated virus vectors for the treatment of mucopolysaccharidoses type IV A19 Nov 2024US 12,146,169 B2Esteve Pharmaceuticals, S.A.
- Method of treating mucopolysaccharidosis type IVA19 Dec 2023US 11,844,825 B2Saint Louis University
- Chondrosulphatase and use thereof6 Jun 2023US 11,667,901 B2Nanjing Hanxin Pharmaceutical Inc
- Gene therapy19 Feb 2026US 2026/0048148 A1Fondazione Telethon Ets (50%)
- Glyco-Engineered Yeast for Therapeutic Protein Production12 Feb 2026US 2026/0042998 A1Universiteit Gent
- Adenoassociated virus vectors for the treatment of mucopolysaccharidoses type iv a6 Mar 2025US 2025/0075194 A1Esteve Pharmaceuticals, S.A.
- Injectable high concentration pharmaceutical formulations and methods of manufacturing and use thereof16 Mar 2023US 2023/0085357 A1Xeris Pharmaceuticals, Inc.
- Treatment of mucopolysaccharidosis iva2 Mar 2023US 2023/0064077 A1REGENXBIO Inc.
Most cited
By later US patents
- Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor61US 5,695,752 AThe Regents of the University of California · 1997
- Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereof5US 8,765,437 B2Biomarin Pharmaceutical Inc. · 2014
- Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor3US 5,925,349 AThe Regents of the University of California · 1999
- Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereof2US 8,940,513 B2Biomarin Pharmaceutical Inc. · 2015
- Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereof1US 9,567,572 B2Biomarin Pharmaceutical Inc. · 2017